Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma
Clinical trial NCT02482532 · COMPLETED
Trial details
- NCT number
- NCT02482532
- Sponsor
- Gary Doolittle
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-06
- Primary completion
- 2019-10-10
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.